The global cardiac marker testing market is on track for sustained growth, according to research from Kalorama Information’s IVD Business Outlook. As cardiovascular disease remains a leading cause of mortality worldwide, demand for rapid and accurate diagnostic testing continues to rise.

Kalorama’s latest analysis highlights that while traditional lab-based cardiac marker testing remains the dominant segment, the point-of-care (POC) segment is gaining ground at a faster pace—reflecting growing interest in decentralized and near-patient diagnostics. The article projects continued market expansion through 2029, supported by adoption of high-sensitivity assays and increasing procedure volumes globally.

“The shift toward point-of-care cardiac testing reflects a broader transformation in healthcare delivery,” said Daniel Granderson, Senior Editor of Kalorama Information. “Providers are seeking faster diagnostic tools that enable quicker clinical decisions, especially in emergency and acute care settings.”

Cardiac biomarkers such as troponin, BNP, CK-MB, and myoglobin remain central to acute care diagnostics, accounting for the vast majority of test volumes. North America and Europe collectively account for more than three-quarters of global market share, while the Asia Pacific region continues to emerge as a high-potential growth area.

The article also profiles major players shaping the market landscape, including Danaher (via Beckman Coulter and Radiometer), Siemens Healthineers, QuidelOrtho, Roche, and Abbott. Recent product launches, regulatory approvals, and shifts in diagnostic testing demand—particularly post-pandemic—are helping to reshape vendor dynamics and innovation priorities.
For more insights on market forecasts, regional dynamics, and comprehensive market views, visit Kalorama Information’s IVD Business Outlook.